JPRN-jRCT2051210027尚未招募1 期
A Randomized, Single-Center, Double-Blind, Placebo-Controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SCO-240 in Healthy Adult Subjects
Araki Takahiro0 个研究点目标入组 76 人开始时间: 2021年5月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •Gender: Male
- •Healthy Japanese adults: The subject's parents and grand parents are Japanese
- •Healthy Caucasian adults: The subject's parents and grandparents are Caucasian
- •- Age: Subjects are between 20 and 45 years, inclusive, at the time of informed consent
- •- Weight at screening:
- •Healthy Japanese adults: >=50 kg, body mass index (BMI) >=18.5 kg/m2 and =<25.0 kg/m2
- •Healthy Caucasian adults >=50 kg, BMI >=18.5 kg/m2 and =<30.0 kg/m2
排除标准
- •- Subjects who have a present illness such as cardiovascular disease, central nervous system disease, gastrointestinal disease, hematopoietic disease, renal failure, metabolic or endocrine disorder, serious allergy, asthma, hypoxemia, hypertension, convulsion or allergic rash.
研究者
相似试验
撤回
1 期
A Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AD-6626 in Normal, Healthy VolunteersThis study is for healthy volunteers. The intended use of the investigational product is the treatment of Fanconi AnemiaBlood - Haematological diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12615000601538Aldea Pharmaceuticals24
招募中
1 期
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of KDF-07002 in Healthy, Adult VolunteersThis trial is to assess safety and tolerability of KDF-07002 in healthy adult males and dose not focus on any particular health condition or problemOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12609000086268ucleus Network, Ltd.54
已完成
1 期
A Single-Center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of Various Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia.Skin - Dermatological conditionsAndrogenetic AlopeciaACTRN12613000974707Samumed LLC30
已完成
1 期
A Single-Center, Randomized, Double-Blind, Placebo Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045 Administered Orally to Normal, Healthy VolunteersPeripheral arterial diseaseACTRN12618000195257Foresee Pharmaceuticals Co., Ltd.24
未知
1 期
Multiple-Dose Phase 1 Study of SCO-792JPRN-jRCT2080223770SCOHIA PHARMA, Inc.36